Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.44%GBPTRY+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%AUDSGD+0.31%GBPUSD+0.31%CADJPY+0.29%NZDSGD+0.29%CHFJPY-0.29%GBPMXN-0.28%USDTRY+0.28%NZDUSD+0.27%AUDUSD+0.27%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%USDZAR-0.21%GBPJPY+0.21%GBPSGD+0.20%USDCHF+0.20%EURAUD-0.18%USDPLN-0.17%AUDJPY+0.17%USDSEK-0.16%EURNOK-0.16%USDILS+0.16%NZDCAD-0.16%EURNZD-0.16%CHFNOK-0.16%CHFSGD+0.16%AUDDKK+0.16%NOKJPY+0.16%SGDJPY-0.16%NZDJPY+0.15%EURSGD+0.15%AUDCAD-0.13%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%USDJPY-0.10%GBPCAD-0.08%GBPZAR-0.07%EURCNH+0.07%EURPLN-0.07%EURSEK-0.07%EURUSD+0.06%CHFSEK-0.06%PLNJPY+0.06%GBPAUD+0.06%USDSGD+0.05%GBPNZD+0.04%USDCOP-0.04%USDCNH-0.03%EURJPY-0.03%AUDNZD+0.02%USDTHB+0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%COTTON+0.73%HG1+0.72%S1+0.48%XNGUSD+0.32%W1-0.24%XAGUSD+0.22%GAGUSD+0.22%UKOIL-0.16%USOIL-0.14%XAUUSD+0.11%GAUUSD+0.11%XPTUSD+0.05%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.52%DOGEUSD+14.12%XMRUSDT+5.79%LINKUSD+13.42%XLMUSD+0.25%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.36%HBARUSDT+0.40%TONUSD+26.15%TAOUSDT+3.79%AAVEUSD+3.57%DOTUSDT-0.20%ICPUSDT+0.88%ONDOUSDT+0.38%WLDUSDT-0.21%ARBUSDT+6.76%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.23%STXUSDT+6.76%FETUSDT+2.77%TIAUSDT+9.19%PYTHUSDT-0.84%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.86%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.75%DYDXUSDT+3.35%GALAUSDT-1.87%ORDIUSDT-0.12%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.60%GBPCHF+0.52%AUDCHF+0.46%NZDCHF+0.44%GBPTRY+0.41%USDCAD-0.40%EURCAD-0.35%GBPHKD+0.32%AUDSGD+0.31%GBPUSD+0.31%CADJPY+0.29%NZDSGD+0.29%CHFJPY-0.29%GBPMXN-0.28%USDTRY+0.28%NZDUSD+0.27%AUDUSD+0.27%USDNOK-0.26%EURCHF+0.25%EURGBP-0.23%NZDMXN+0.23%USDZAR-0.21%GBPJPY+0.21%GBPSGD+0.20%USDCHF+0.20%EURAUD-0.18%USDPLN-0.17%AUDJPY+0.17%USDSEK-0.16%EURNOK-0.16%USDILS+0.16%NZDCAD-0.16%EURNZD-0.16%CHFNOK-0.16%CHFSGD+0.16%AUDDKK+0.16%NOKJPY+0.16%SGDJPY-0.16%NZDJPY+0.15%EURSGD+0.15%AUDCAD-0.13%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%USDJPY-0.10%GBPCAD-0.08%GBPZAR-0.07%EURCNH+0.07%EURPLN-0.07%EURSEK-0.07%EURUSD+0.06%CHFSEK-0.06%PLNJPY+0.06%GBPAUD+0.06%USDSGD+0.05%GBPNZD+0.04%USDCOP-0.04%USDCNH-0.03%EURJPY-0.03%AUDNZD+0.02%USDTHB+0.02%USDMXN-0.01%EURCZK+0.01%USDHKD+0.01%AUDNOK0.00%EURDKK0.00%COTTON+0.73%HG1+0.72%S1+0.48%XNGUSD+0.32%W1-0.24%XAGUSD+0.22%GAGUSD+0.22%UKOIL-0.16%USOIL-0.14%XAUUSD+0.11%GAUUSD+0.11%XPTUSD+0.05%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.52%DOGEUSD+14.12%XMRUSDT+5.79%LINKUSD+13.42%XLMUSD+0.25%BCHUSDT+5.89%UNIUSD+7.49%LTCUSD+9.66%SUIUSD+3.36%HBARUSDT+0.40%TONUSD+26.15%TAOUSDT+3.79%AAVEUSD+3.57%DOTUSDT-0.20%ICPUSDT+0.88%ONDOUSDT+0.38%WLDUSDT-0.21%ARBUSDT+6.76%JUPUSDT+0.62%ATOMUSDT+1.90%INJUSDT+13.23%STXUSDT+6.76%FETUSDT+2.77%TIAUSDT+9.19%PYTHUSDT-0.84%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+18.94%GRTUSDT+4.09%IOTAUSDT+0.86%WIFUSDT+2.70%AXSUSDT-1.83%POLUSDT+2.78%FARTCOINUSDT+0.63%EOSUSDT+2.75%DYDXUSDT+3.35%GALAUSDT-1.87%ORDIUSDT-0.12%RONINUSDT-3.42%NOTUSDT+1.21%
VT

Vera Therapeutics, Inc. (VERA)

NASDAQ • Healthcare

$26.79
-$0.92 (-3.4%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$27.62
Day Range$26.55 - $27.73
Avg. Volume (3M)2.5M
Market Cap$1.9B
52 Week Range
$23.05$56.05
Next EarningsIn 21 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$401.8M
EPS (TTM)
-$5.86
ROA (TTM)
-75.4%
Current Ratio
10.92

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-3.7%Q1 2026-$1.39
-27.2%Q2 2026-$1.69
+3.8%Q3 2026-$1.52
Next

Nov 4

in 21 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +3.8%

Vera Therapeutics’ loss per share topped expectations even as the company posted a wider year-over-year net loss, based on preliminary results for the second fiscal quarter of 2026 reported August 10, 2026. EPS of -$1.52 topped the -$1.58 estimate by $0.06, and was down -26.7% from -$1.20 a year ago as the clinical-stage biotech continued investing in its lead programs, including atacicept and MAU868. Net income was a loss of roughly $109.5 million, down -43.0% from a loss of about $76.5 million a year ago, while operating income came in at a loss of about $112.5 million. Cash use remained elevated, with negative operating cash flow of roughly $100.3 million in the quarter. For the next period, consensus calls for EPS of -$1.61 on revenue of $4.3 million.

Next report — what to expect

Vera Therapeutics, Inc. (VERA) is scheduled to report on November 4, 2026. Wall Street is looking for EPS of -$1.609 on revenue of $4.3 million. In recent history, the company has beaten EPS expectations in 2 of its 8 most recent quarters.

View full earnings history

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that develops medicines for serious diseases. The company is a small-cap clinical-stage drug developer focused on two lead programs, atacicept and MAU868, and operates in the United States from a base in Brisbane, California.

Name
Vera Therapeutics, Inc.
CEO
Marshall Fordyce
Website
veratx.com
Industry
Healthcare
Year Founded
2016
Employees
361

Today's Snapshot

AI-generated

VERA closed 3.4% lower on heavier trading than usual.

Trading Volume

Above 10d avg 2.0M

2.8M

vs S&P 500 Today

Strong Underperformance

-3.33%

Updated: October 13, 2026 at 20:10 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
With the stock near 26.79 the technicals are mixed, producing a neutral posture: short-term oscillators read as oversold and stochastic measures show buying interest, yet MACD and momentum remain weak and the price is below most medium- and long-term moving averages. Trend strength is muted, and on-balance volume is negative, suggesting limited conviction behind short-term bounces. Bollinger metrics indicate the market is testing lower bands while volatility is elevated. Technical takeaway: overall Neutral — short-term oversold signals counterbalanced by a broader downtrend and low trend conviction.
All signals
  • EMA (5 indicators)$29.58 - $36.28
    Sell
  • RSI (14)29.54
    Buy
  • Stochastic %K (14, 3, 3)7.61
    Buy
  • MACD Level (12, 26)-1.50
    Sell

Peers & Related Assets

DNTHDianthus Therapeutics, Inc.
$77.58-4.9%
ARQTArcutis Biotherapeutics, Inc.
$26.09-0.5%
BHVNBiohaven Ltd.
$11.42-3.3%
ANABAnaptysBio, Inc.
$45.59-1.0%
ALMSAlumis Inc.
$6.56-7.1%
MLTXMoonLake Immunotherapeutics
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.